[go: up one dir, main page]

WO2003002529A3 - Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3, 4-dihydro-2(1h)-quinolinone - Google Patents

Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3, 4-dihydro-2(1h)-quinolinone Download PDF

Info

Publication number
WO2003002529A3
WO2003002529A3 PCT/US2002/022085 US0222085W WO03002529A3 WO 2003002529 A3 WO2003002529 A3 WO 2003002529A3 US 0222085 W US0222085 W US 0222085W WO 03002529 A3 WO03002529 A3 WO 03002529A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymorphs
quinolinone
tetrazol
butoxy
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/022085
Other languages
French (fr)
Other versions
WO2003002529A2 (en
Inventor
Grayson Walker Stowell
Robert R Whittle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AAIPharma Inc
Original Assignee
AAIPharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/896,185 external-priority patent/US20030045548A1/en
Priority claimed from US09/896,184 external-priority patent/US6531603B1/en
Priority claimed from US09/896,800 external-priority patent/US6596871B2/en
Application filed by AAIPharma Inc filed Critical AAIPharma Inc
Priority to AU2002322456A priority Critical patent/AU2002322456A1/en
Publication of WO2003002529A2 publication Critical patent/WO2003002529A2/en
Publication of WO2003002529A3 publication Critical patent/WO2003002529A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Polymorphs Form B, Form C, and amorphous of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, commonly known as cilostazol, have been identified. These polymorphs may be formed in pure form, in combination with each other, in combination with other polymorphs of cilostazol, or together with other pharmaceutical agents. Processes for preparing these polymorphs, and combinations of these polymorphs, as well as methods of use and unit dosages of these polymorphic forms, and their combinations, are described.
PCT/US2002/022085 2001-06-29 2002-06-28 Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3, 4-dihydro-2(1h)-quinolinone Ceased WO2003002529A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002322456A AU2002322456A1 (en) 2001-06-29 2002-06-28 Polymorphic forms of 6-(4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy)-3, 4-dihydro-2(1h)-quinolinone

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/896,185 US20030045548A1 (en) 2001-06-29 2001-06-29 Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-YL)butoxy]-3,4-dihydro-2(1H)-quinolinone
US09/896,185 2001-06-29
US09/896,184 US6531603B1 (en) 2001-06-29 2001-06-29 Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US09/896,800 US6596871B2 (en) 2001-06-29 2001-06-29 Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetraol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US09/896,800 2001-06-29
US09/896,184 2001-06-29

Publications (2)

Publication Number Publication Date
WO2003002529A2 WO2003002529A2 (en) 2003-01-09
WO2003002529A3 true WO2003002529A3 (en) 2003-05-08

Family

ID=27420565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/022085 Ceased WO2003002529A2 (en) 2001-06-29 2002-06-28 Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3, 4-dihydro-2(1h)-quinolinone

Country Status (2)

Country Link
AU (1) AU2002322456A1 (en)
WO (1) WO2003002529A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4277479A (en) * 1978-09-01 1981-07-07 Otsuka Pharmaceutical Co., Ltd. Tetrazolylalkoxycarbostyril derivatives and pharmaceutical compositions containing them
US4728653A (en) * 1984-05-29 1988-03-01 Pfizer Inc. 6-heteroaryl quinolone inotropic agents
US6388080B1 (en) * 2001-06-29 2002-05-14 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4277479A (en) * 1978-09-01 1981-07-07 Otsuka Pharmaceutical Co., Ltd. Tetrazolylalkoxycarbostyril derivatives and pharmaceutical compositions containing them
US4728653A (en) * 1984-05-29 1988-03-01 Pfizer Inc. 6-heteroaryl quinolone inotropic agents
US6388080B1 (en) * 2001-06-29 2002-05-14 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone

Also Published As

Publication number Publication date
AU2002322456A1 (en) 2003-03-03
WO2003002529A2 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
AU2003209119A1 (en) Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
IL164292A0 (en) Quinoline and isoquinoline derivatives, method forthe production thereof and use thereof as anti-in flammatory agents
WO2007033266A3 (en) Dipeptidyl peptidase inhibitors for treating diabetis
EE200100167A (en) 4-amino-substituted 2-substituted 1,2,3,4-tetrahydroquinolines as CETP inhibitors
EP1837331A3 (en) New crystalline aripiprazole salts and processes for preparation and purification thereof
BRPI0407904A (en) process for the preparation of useful 5 - [(r) -2- (5,6-diethyl-indan-2-ylain) -1-hydroxy-ethyl] -8-hydroxy (1h) -quinolin-2-one salt as an adrenoceptor agonist
NO20072963L (en) 5-substituted quinoline and isoquinoline derivatives, process for their preparation and their use as inflammatory inhibitors
WO2004103960A3 (en) Compounds and uses thereof
IS2581B (en) Quinoline derivatives inhibited by phosphodiesterase
WO2005023192A3 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2006127926A3 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
WO2009149259A3 (en) Processes for preparing tetrahydroisoquinolines
WO2003022209A3 (en) Crystalline forms of valacyclovir hydrochloride
WO2004050036A3 (en) Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
WO2008039639A3 (en) Substituted thienopyridone compounds with antibacterial activity
IL179709A0 (en) 4-substituted quinoline derivatives, method and intermediates for preparing same and pharmaceutical compositions containing same
WO2004034985A3 (en) Chemical compounds
WO2003002529A3 (en) Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3, 4-dihydro-2(1h)-quinolinone
NO20030699L (en) Process for the preparation of cilostazole
WO2008146156A3 (en) An improved process for the preparation of aripiprazole
MXPA05011677A (en) Benzofuranyl-and benzothienyl-piperazinyl quinolines as serotonin reuptake inhib itors.
AU2003224482A1 (en) Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
WO2004022542A3 (en) Substituted 1,2,3,4-tetrahydroquinoline derivatives
BRPI0407903A (en) protomicroemulsion, cleaning implement containing it, and method of use thereof
AU2003230831A1 (en) ANHYDROUS CRYSTALLINE FORMS I AND II OF 1-CYCLOPROPYL-6-FLUORO-8-METHOXY-7-(3-METHYL-1-PIPERAZINYL) 4-OXO-l, 4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID (GATIFLOXACIN)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP